MX2017016519A - Biomarcadores para composiciones de nanoparticulas. - Google Patents

Biomarcadores para composiciones de nanoparticulas.

Info

Publication number
MX2017016519A
MX2017016519A MX2017016519A MX2017016519A MX2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A
Authority
MX
Mexico
Prior art keywords
biomarkers
nanoparticle compositions
compositions
mtor
limo
Prior art date
Application number
MX2017016519A
Other languages
English (en)
Spanish (es)
Inventor
P Desai Neil
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of MX2017016519A publication Critical patent/MX2017016519A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1658Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2017016519A 2015-06-29 2016-06-29 Biomarcadores para composiciones de nanoparticulas. MX2017016519A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562186309P 2015-06-29 2015-06-29
PCT/US2016/040196 WO2017004264A1 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions

Publications (1)

Publication Number Publication Date
MX2017016519A true MX2017016519A (es) 2018-08-16

Family

ID=57609078

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016519A MX2017016519A (es) 2015-06-29 2016-06-29 Biomarcadores para composiciones de nanoparticulas.
MX2023013010A MX2023013010A (es) 2015-06-29 2017-12-15 Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023013010A MX2023013010A (es) 2015-06-29 2017-12-15 Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor.

Country Status (10)

Country Link
US (3) US20180177771A1 (OSRAM)
EP (1) EP3313381A4 (OSRAM)
JP (4) JP2018527308A (OSRAM)
KR (2) KR20240144442A (OSRAM)
AU (3) AU2016285727B9 (OSRAM)
CA (1) CA2990703C (OSRAM)
HK (1) HK1254398A1 (OSRAM)
IL (2) IL312318A (OSRAM)
MX (2) MX2017016519A (OSRAM)
WO (1) WO2017004264A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2117520T3 (en) 2006-12-14 2019-01-07 Abraxis Bioscience Llc BREAST CANCER THERAPY BASED ON HORMON RECEPTOR STATUS WITH NANOPARTICLES INCLUDING TAXAN
AU2010236382B2 (en) 2009-04-15 2016-01-14 Abraxis Bioscience, Llc Prion-free nanoparticle compositions and methods
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
JP6038123B2 (ja) 2011-04-28 2016-12-07 アブラクシス バイオサイエンス, エルエルシー ナノ粒子組成物の脈管内送達およびそれらの使用
SI2790675T1 (sl) 2011-12-14 2019-11-29 Abraxis Bioscience Llc Uporaba polimernih pomožnih snovi za liofilizacijo ali zamrzovanje delcev
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
CN110934852A (zh) 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
CN116585310A (zh) 2015-06-29 2023-08-15 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
WO2019140257A1 (en) * 2018-01-11 2019-07-18 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing and treating prostate cancer
AU2019239953B2 (en) * 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
MX2020012478A (es) * 2018-05-22 2021-03-09 Abraxis Bioscience Llc Metodos y composiciones para el tratamiento de la hipertension pulmonar.
CN111187834B (zh) * 2019-01-08 2021-01-22 中国科学院上海营养与健康研究所 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
US20220054404A1 (en) * 2019-03-19 2022-02-24 Abraxis Bioscience, Llc Subcutaneous administration of nanoparticles comprising an mtor inhibitor and albumin for treatment of diseases
EP4051241A4 (en) 2019-10-28 2023-12-06 Abraxis BioScience, LLC PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN
EP4058000A4 (en) * 2019-11-11 2024-02-28 Abraxis BioScience, LLC BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
AU2021358768A1 (en) * 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
WO2022186673A1 (ko) * 2021-03-05 2022-09-09 전남대학교산학협력단 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘
WO2024215799A1 (en) * 2023-04-11 2024-10-17 Leapfrog Bio, Inc. Pi3k inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2481409T (lt) * 2007-03-07 2018-10-25 Abraxis Bioscience, Llc Nanodalelės, apimančios rapamiciną ir albuminą, kaip priešvėžinį agentą
US20130266659A1 (en) * 2010-06-02 2013-10-10 Neil P. Desai Methods of treating bladder cancer
BR112013016708B1 (pt) * 2010-12-30 2021-08-17 Foundation Medicine, Inc Otimização de análise multigene de amostras de tumor
CN110934852A (zh) * 2013-03-14 2020-03-31 阿布拉科斯生物科学有限公司 治疗膀胱癌的方法
WO2014144451A2 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Biomarkers for response to rapamycin analogs
CA2990726A1 (en) * 2015-06-29 2017-01-05 Abraxis Bioscience, Llc Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy

Also Published As

Publication number Publication date
IL312318A (en) 2024-06-01
AU2016285727A1 (en) 2018-02-01
IL256326B2 (en) 2024-09-01
JP2023071656A (ja) 2023-05-23
HK1254398A1 (zh) 2019-07-19
JP2021169457A (ja) 2021-10-28
JP2018527308A (ja) 2018-09-20
US20230080409A1 (en) 2023-03-16
EP3313381A4 (en) 2019-02-27
AU2021290200A1 (en) 2022-01-20
AU2016285727B9 (en) 2021-09-30
KR20180019230A (ko) 2018-02-23
US20250152563A1 (en) 2025-05-15
EP3313381A1 (en) 2018-05-02
WO2017004264A1 (en) 2017-01-05
AU2021290200B2 (en) 2024-05-02
IL256326A (en) 2018-02-28
MX2023013010A (es) 2023-11-15
AU2024204661A1 (en) 2024-07-25
CA2990703C (en) 2024-04-30
US20180177771A1 (en) 2018-06-28
CA2990703A1 (en) 2017-01-05
KR102708679B1 (ko) 2024-09-24
KR20240144442A (ko) 2024-10-02
AU2016285727B2 (en) 2021-09-23
IL256326B1 (en) 2024-05-01
JP2025097987A (ja) 2025-07-01

Similar Documents

Publication Publication Date Title
MX2017016519A (es) Biomarcadores para composiciones de nanoparticulas.
CY1124926T1 (el) Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
MX378934B (es) Composición de nanopartículas para usarse en el tratamiento de cáncer de vejiga
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
MX2019009361A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias.
HK1217292A1 (zh) 基於k- ras的突变状态治疗癌症的方法
MX2020001550A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CO2018008846A2 (es) Derivados de carboxamida útiles como inhibidores de rsk
MX369863B (es) Ciertas entidades quimicas, composiciones y metodos.
CR20160363A (es) Heteroarilos y usos de estos
MX2018011992A (es) Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos.
MX2015015738A (es) Derivados del bipirazol como inhibidores de janus cinasa (jak).
MX385315B (es) Composiciones y metodos para inhibir actividad de arginasa.
CR20120528A (es) Métodos para tratar el cáncer
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2019003397A (es) Metodos para tratar trastornos mitocondriales y metabolicos.
MX2017004600A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PH12017501879A1 (en) Methods for treating cancer
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden
ECSP14027694A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
BR112018013928A2 (pt) composições terapêuticas e métodos para tratamento da hepatite b